Saphenous vein graft stenting and major adverse cardiac events: a predictive model derived from a pooled analysis of 3958 patients.

@article{Coolong2008SaphenousVG,
  title={Saphenous vein graft stenting and major adverse cardiac events: a predictive model derived from a pooled analysis of 3958 patients.},
  author={Alanna Coolong and Donald S. Baim and Richard E. Kuntz and A. James O'Malley and Sachin Marulkar and Donald E. Cutlip and Jeffrey J. Popma and Laura Mauri},
  journal={Circulation},
  year={2008},
  volume={117 6},
  pages={790-7}
}
BACKGROUND Treatment of saphenous vein graft (SVG) stenosis with percutaneous coronary intervention has a 15% to 20% incidence of major adverse cardiac events (MACE) within 30 days. Although MACE rates are reduced significantly by the use of embolic protection devices (EPDs), neither the level of baseline risk nor the benefit provided by EPDs has been well characterized. METHODS AND RESULTS Data from 5 randomized controlled trials and 1 registry evaluating EPDs in SVG percutaneous coronary… CONTINUE READING